{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-033456","form_type":"8-K","ticker":"APYX","cik":"0000719135","company_name":"Apyx Medical Corp","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.996138+00:00","generated_at":"2026-05-17T00:05:19.747707+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Apyx Medical Q3 rev $12.9M (+12% YoY); net loss $2.0M; raises FY guidance to $50.5-52.5M","bullets":["Total revenue $12.9M (+12% YoY); Surgical Aesthetics $11.1M (+19% YoY).","Net loss attributable to stockholders $2.0M ($0.05/sh) vs $4.7M loss in Q3 2024.","Adjusted EBITDA loss improved 96% to $0.1M from $2.4M in Q3 2024.","FY2025 revenue guidance raised to $50.5-52.5M (prev $50-52M); Surgical Aesthetics segment guided at $43-45M.","Initiated full U.S. commercial launch of AYON Body Contouring System; submitted 510(k) for power liposuction label expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-033456","json":"https://secwatch.observer/filing/0001437749-25-033456.json","markdown":"https://secwatch.observer/filing/0001437749-25-033456.md","text":"https://secwatch.observer/filing/0001437749-25-033456.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/719135/000143774925033456/0001437749-25-033456-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/719135/000143774925033456/apyx20250816_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:05:19.747707+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}